FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2975554022> ?p ?o ?g. }

• W2975554022 endingPage "4031" @default.
• W2975554022 startingPage "4031" @default.
• W2975554022 abstract "INTRODUCTION: Early assessment of tumor response in chronic lymphocytic leukemia (CLL) can be difficult during ibrutinib therapy due to treatment-related lymphocytosis and concern for radiation exposure that limits the frequency of computed tomography (CT). B-cell maturation antigen (BCMA), a member of the tumor necrosis factor super family receptors, is overexpressed in CLL. In another mature B-cell malignancy, multiple myeloma, elevated serum (s) BCMA has been associated with inferior therapeutic response and survival. It was previously shown that sBCMA levels are increased in CLL and correlated with time to first treatment and overall survival. To evaluate its utility as a biomarker in the context of targeted therapy, we assessed sBCMA in CLL patients during treatment with ibrutinib. METHODS: BCMA levels were measured in the serum of 46 patients enrolled on a phase 2 study of ibrutinib for CLL (NCT01500733). The following time points were evaluated: baseline, day 2, and 1, 2, 6, 12, 24, 36, 48 months (M) after starting ibrutinib, as well as at the time of progressive disease (PD), if available. sBCMA was measured using a sandwich ELISA (R&D Systems). Lymphadenopathy was measured by the sum of the product of the diameters (SPD). Signed-rank test, rank-sum test and Spearman correlation were performed to compare sBCMA between categorical and continuous variables. RESULTS: Baseline disease characteristics included relapsed or refractory CLL in 15 patients (33%), 17p deletion in 31 (67%), unmutated IGHV in 33 (72%), and advanced Rai stage in 32 (70%). The median age was 67 years (range 39-81) and 26 patients (57%) were male. At baseline, the median sBCMA was 145 ng/mL (range 24-376) and significantly higher among patients with 17p deletion than those without (median 179.6 versus 75.8, P = 0.033). sBCMA was not different with respect to prior treatment status, IGHV mutation, or Rai stage. A weak correlation between sBCMA and known serologic indicators of tumor burden and activity, β2-microglobulin (r = 0.36, P = 0.02) and lactate dehydrogenase (r = 0.41, P = 0.006), was also observed. sBCMA decreased as early as day 2 (median decrease 15%, P = 0.003) and progressively decreased during the first year of ibrutinib therapy (median decrease 79%, P Next, we retrospectively measured sBCMA in 13 patients from whom serum was collected within 3M of PD to evaluate whether it could be used to predict PD. Baseline sBCMA was not significantly different between patients who later developed PD and those who did not. Among patients who developed PD, sBCMA reached a nadir after a median of 12M on ibrutinib therapy before gradually increasing until the time of PD (median increase 153% [interquartile range, IQR 81%-314%] from nadir). The initial increase in sBCMA was observed at a median of 8.4M (range 0-20.2) before clinical progression. In contrast, patients who remained in remission experienced lesser fluctuations in sBCMA (median increase 20% [IQR 0%-43%] from nadir). The increase in sBCMA from nadir among PD cases was significantly greater than non-PD cases (P CONCLUSION: sBCMA rapidly decreased during treatment with ibrutinib. Decrease in sBCMA was associated with reduction in lymphadenopathy, while an increase in sBCMA from nadir often preceded clinical PD. sBCMA represents a potential biomarker for monitoring response and detecting disease progression in CLL patients treated with ibrutinib. This research was supported by the Intramural Research Program of NHLBI. Pharmacyclics, an Abbvie company provided ibrutinib and research support. Disclosures Berenson: OncoTracker, Inc.: Employment, Equity Ownership, Membership on an entity9s Board of Directors or advisory committees; Incyte: Consultancy, Research Funding. Wiestner: Acerta Pharma: Research Funding; Pharmacyclics: Research Funding." @default.
• W2975554022 created "2019-10-03" @default.
• W2975554022 creator A5015712500 @default.
• W2975554022 creator A5028491175 @default.
• W2975554022 creator A5030524385 @default.
• W2975554022 creator A5038321186 @default.
• W2975554022 creator A5038431825 @default.
• W2975554022 creator A5040835019 @default.
• W2975554022 creator A5044039905 @default.
• W2975554022 creator A5051959420 @default.
• W2975554022 creator A5066494072 @default.
• W2975554022 creator A5070458905 @default.
• W2975554022 creator A5073077636 @default.
• W2975554022 creator A5090300095 @default.
• W2975554022 date "2017-12-07" @default.
• W2975554022 modified "2023-09-27" @default.
• W2975554022 title "Serum B-Cell Maturation Antigen As a Biomarker for Chronic Lymphocytic Leukemia Treated with Ibrutinib" @default.
• W2975554022 doi "https://doi.org/10.1182/blood.v130.suppl_1.4031.4031" @default.
• W2975554022 hasPublicationYear "2017" @default.
• W2975554022 type Work @default.
• W2975554022 sameAs 2975554022 @default.
• W2975554022 citedByCount "0" @default.
• W2975554022 crossrefType "journal-article" @default.
• W2975554022 hasAuthorship W2975554022A5015712500 @default.
• W2975554022 hasAuthorship W2975554022A5028491175 @default.
• W2975554022 hasAuthorship W2975554022A5030524385 @default.
• W2975554022 hasAuthorship W2975554022A5038321186 @default.
• W2975554022 hasAuthorship W2975554022A5038431825 @default.
• W2975554022 hasAuthorship W2975554022A5040835019 @default.
• W2975554022 hasAuthorship W2975554022A5044039905 @default.
• W2975554022 hasAuthorship W2975554022A5051959420 @default.
• W2975554022 hasAuthorship W2975554022A5066494072 @default.
• W2975554022 hasAuthorship W2975554022A5070458905 @default.
• W2975554022 hasAuthorship W2975554022A5073077636 @default.
• W2975554022 hasAuthorship W2975554022A5090300095 @default.
• W2975554022 hasConcept C126322002 @default.
• W2975554022 hasConcept C143998085 @default.
• W2975554022 hasConcept C151730666 @default.
• W2975554022 hasConcept C203014093 @default.
• W2975554022 hasConcept C2777609679 @default.
• W2975554022 hasConcept C2777938653 @default.
• W2975554022 hasConcept C2778461978 @default.
• W2975554022 hasConcept C2779343474 @default.
• W2975554022 hasConcept C2779878957 @default.
• W2975554022 hasConcept C2780126324 @default.
• W2975554022 hasConcept C2781197716 @default.
• W2975554022 hasConcept C2781442060 @default.
• W2975554022 hasConcept C55493867 @default.
• W2975554022 hasConcept C71924100 @default.
• W2975554022 hasConcept C86803240 @default.
• W2975554022 hasConcept C90924648 @default.
• W2975554022 hasConceptScore W2975554022C126322002 @default.
• W2975554022 hasConceptScore W2975554022C143998085 @default.
• W2975554022 hasConceptScore W2975554022C151730666 @default.
• W2975554022 hasConceptScore W2975554022C203014093 @default.
• W2975554022 hasConceptScore W2975554022C2777609679 @default.
• W2975554022 hasConceptScore W2975554022C2777938653 @default.
• W2975554022 hasConceptScore W2975554022C2778461978 @default.
• W2975554022 hasConceptScore W2975554022C2779343474 @default.
• W2975554022 hasConceptScore W2975554022C2779878957 @default.
• W2975554022 hasConceptScore W2975554022C2780126324 @default.
• W2975554022 hasConceptScore W2975554022C2781197716 @default.
• W2975554022 hasConceptScore W2975554022C2781442060 @default.
• W2975554022 hasConceptScore W2975554022C55493867 @default.
• W2975554022 hasConceptScore W2975554022C71924100 @default.
• W2975554022 hasConceptScore W2975554022C86803240 @default.
• W2975554022 hasConceptScore W2975554022C90924648 @default.
• W2975554022 hasLocation W29755540221 @default.
• W2975554022 hasOpenAccess W2975554022 @default.
• W2975554022 hasPrimaryLocation W29755540221 @default.
• W2975554022 hasRelatedWork W126125533 @default.
• W2975554022 hasRelatedWork W204478610 @default.
• W2975554022 hasRelatedWork W2396270966 @default.
• W2975554022 hasRelatedWork W2434582744 @default.
• W2975554022 hasRelatedWork W2512103032 @default.
• W2975554022 hasRelatedWork W2529112261 @default.
• W2975554022 hasRelatedWork W2547502956 @default.
• W2975554022 hasRelatedWork W2550063510 @default.
• W2975554022 hasRelatedWork W2558296790 @default.
• W2975554022 hasRelatedWork W2588501001 @default.
• W2975554022 hasRelatedWork W2592551916 @default.
• W2975554022 hasRelatedWork W2617199478 @default.
• W2975554022 hasRelatedWork W2781589685 @default.
• W2975554022 hasRelatedWork W2901100437 @default.
• W2975554022 hasRelatedWork W2973947607 @default.
• W2975554022 hasRelatedWork W2979447390 @default.
• W2975554022 hasRelatedWork W2980405244 @default.
• W2975554022 hasRelatedWork W3196771116 @default.
• W2975554022 hasRelatedWork W3199200396 @default.
• W2975554022 hasRelatedWork W3213252454 @default.
• W2975554022 hasVolume "130" @default.
• W2975554022 isParatext "false" @default.
• W2975554022 isRetracted "false" @default.
• W2975554022 magId "2975554022" @default.
• W2975554022 workType "article" @default.